TREATMENT OF DYSLIPIDEMIAS
 
Generic Brand Company Formulation Indications1

 

Slow
coronary
athero-
sclerosis		  Lower 
total-C		 Lower
LDL-C		 Increase
HDL-C		 Lower
apo B		 Lower
TG		 Sitosterol/
campesterol		 Reduce risk of morbidity/
mortality
BILE ACID SEQUESTRANTS
Colesevelam Welchol Daiichi-Sankyo tabs, oral susp √
Cholestyramine resin Questran and Questran Light Par pwd √ √ √
Colestipol Colestid Pfizer tabs, granules √ √
CHOLESTEROL ABSORPTION INHIBITOR
Ezetimibe Zetia Merck/Schering tabs √ √ √ √3
FIBRATES
Fenofibrate Antara Oscient caps √ √ √ √ √
Lipofen Kowa caps √ √ √ √ √
Lofibra Gate tabs, caps √ √ √ √ √
Tricor Abbott tabs √ √ √ √ √
Fenofibric acid Fibricor URL Pharma tabs √ √ √ √ √
Trilipix Abbott caps (del-rel) √ √ √ √ √
Gemfibrozil Lopid Pfizer tabs (scored) √2 √ √
LIPID-REGULATING AGENT
Omega-3-acid ethyl esters Lovaza GSK caps √
NICOTINIC ACID DERIVATIVES
Niacin Niaspan Abbott tabs (ext-rel) √ √ √ √ √ √ √
STATINS (HMG-COA REDUCTASE INHIBITORS)
Atorvastatin Lipitor Pfizer tabs √ √ √ √ √ √
Fluvastatin Lescol Novartis caps √ √ √ √ √ √
Lescol XL Novartis tabs (ext-rel) √ √ √ √ √ √
Lovastatin Mevacor Merck tabs √ √ √ √ √ √
Altoprev Sciele Pharma tabs (ext-rel) √ √ √ √ √ √ √
Pravastatin Pravachol Bristol-Myers Squibb tabs √ √ √ √ √ √ √
Rosuvastatin Crestor AstraZeneca tabs √ √ √4 √ √ √
Simvastatin Zocor Merck tabs √ √ √ √ √ √
COMBINATION STATIN & CALCIUM CHANNEL BLOCKER
Atorvastatin + Amlodipine Caduet Pfizer tabs √ √ √ √ √ √
COMBINATION STATIN & CHOLESTEROL ABSORPTION INHIBITOR
Simvastatin + Ezetimibe Vytorin Merck/Schering tabs √ √ √ √ √
COMBINATION STATIN & NIACIN
Lovastatin + Niacin Advicor Abbott tabs (immediate + ext-rel) √ √ √ √ √
Simvastatin + Niacin Simcor Abbott tabs (immediate + ext-rel) √ √ √ √ √
NOTES

1 FDA-approved for indications (abbreviated here) marked with a √. Not a complete list of official indications. For a more complete description of indications, see indi-vidual product entries and/or contact company for full labeling. Indications listed may be adjunctive to other therapies, including lifestyle changes (eg, diet) and concomitant drugs.

2 Reduction in risk of coronary artery disease when first line agent is inadequate

3 To reduce elevated sitosterol and campes-terol in homozygous familial sitosterolemia

4 Also to reduce elevated non-HDL-C (total-C minus HDL-C)

For more information see the drug entries in this section or contact the company marketing the product.

Classification of Hyperlipoproteinemias
 Fredrickson Type Elevated Lipoproteins Lipid Elevations (Major) Lipid Elevations (Minor)
 I (rare) chylomicrons triglycerides total-C elevated or no change
 IIa LDL total-C —
 IIb LDL, VLDL total-C triglycerides
 III (rare) IDL total-C/triglycerides —
 IV VLDL triglycerides total-C elevated or no change
 V chylomicrons, VLDL triglycerides total-C elevated or no change
ABBREVIATIONS:

apo B = apolipoprotein B;  TG = triglycerides;  total-C = total cholesterol;  LDL-C = low-density lipoproteins;

IDL = intermediate-density lipoproteins;  VLDL = very low density lipoproteins;  HDL-C = high-density lipoproteins

(Rev. 1/2010)